罗莫索单抗治疗骨质疏松的一年临床效果、安全性及疗效预测因素
这项观察性前后对照研究纳入262例骨质疏松患者,皮下注射罗莫索单抗210 mg每4周一次共12个月。一年内新发骨折5例,无致命不良事件;脊柱和全髋骨密度较基线分别变化10.67%和2.04%。既往未用其他抗骨质疏松药物者脊柱骨密度变化百分比更高。
要点
- 罗莫索单抗治疗12个月脊柱骨密度变化百分比为10.67%,全髋为2.04%。
- 一年内新发骨折5例,无致命不良事件。
- 既往未用其他抗骨质疏松药物者脊柱骨密度变化百分比更高。
核心结论
- 罗莫索单抗是脊柱骨质疏松的有效治疗,因其减少新发骨折并显著增加12个月脊柱骨密度变化百分比。
- 脊柱骨密度变化百分比在既往未接受其他抗骨质疏松药物治疗的患者中更高。
研究设计与样本
- 观察性研究,设计为前后对照研究,纳入262例患者。
- 罗莫索单抗210 mg皮下注射,每4周一次,持续12个月。
主要发现
- 一年罗莫索单抗治疗期间新发骨折5例。
- 无致命不良事件。
- 12个月时脊柱和全髋骨密度较基线变化百分比分别为10.67%和2.04%。
- 罗莫索单抗在基线脊柱骨密度低、TRACP-5b高、iP1NP高的严重骨质疏松病例中效果更好。
- 12个月脊柱骨密度变化百分比在从双膦酸盐转换组显著低于既往未用其他抗骨质疏松药物组。
临床怎么用
- 罗莫索单抗可用于脊柱骨质疏松治疗,以降低新发骨折并提高脊柱骨密度。
- 既往未用其他抗骨质疏松药物者可能从罗莫索单抗获得更高的脊柱骨密度变化百分比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Romosozumab is an effective treatment for spine osteoporosis because it reduces the incidence of new fractures and significantly increases the percent change in the spine BMD at 12 months. The percent change in the spine BMD is higher in patients not previously treated with other anti-osteoporosis medications. INTRODUCTION: Romosozumab appeared as a new osteoporosis medication in Japan in 2019. It is an anti-sclerostin antibody, which increases bone formation and suppresses bone resorption. The aim of our study was to elucidate the clinical effects, safety, and predictors of the effects of one-year romosozumab treatment. METHODS: This study was an observational study designed as a pre-post study in 262 patients. Romosozumab (210 mg) was administered subcutaneously once every 4 weeks during 12 months. We focused on incidence of new fractures, safety, bone mineral density (BMD) at the spine and total hip, and bone metabolism markers. RESULTS: There were five cases of new fractures during one-year romosozumab treatment. There were no fatal adverse events. Percent changes from baseline in the spine and total hip BMD after 12 months of romosozumab treatment were 10.67% and 2.04%, respectively. Romosozumab had better effects in cases of severe osteoporosis with low spine BMD, high TRACP-5b, and high iP1NP at the start of romosozumab treatment. The percent change in the spine BMD at 12 months was significantly lower in the group transitioning from bisphosphonates than in the group not previously treated with other anti-osteoporosis medications. CONCLUSION: Romosozumab is an effective treatment for spine osteoporosis because it significantly increases the percent change in the spine BMD at 12 months. The percent change in the spine BMD is higher in patients not previously treated with other anti-osteoporosis medications.
引用
- Tominaga A, Wada K, Okazaki K, et al. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int. 2021. PMID: 33770201. doi:10.1007/s00198-021-05925-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。